We have received word from a source that the Durex Avanti is due to be released in March of 2009. The new Avanti product will no longer be made of Polyurethane instead being manufactured using Polyisoprene, the same material being used to manufacture the new

I get asked the same question time and time again. "Which Condom is the best condom for a buddy of mine that is not so well endowed?" This is probably the most asked question i receive on a daily basis.

Many customers ask us about lubricants, which are best, which contain benzocaine, etc... Below is some info to help you find the right personal lubricant. Please Note: All lubes on our website are safe for use with condoms and toys unless otherwise noted.

"It's a tantra master wrapped in foil, the antidote to impatient passion. Two lines of "climax control" condoms that contain a mild anethetic, Benzocaine, promise men the sort of self-restraint that once required tantric meditation or at least a distracting thought or two during sex.

Genital HPV infection is a sexually transmitted disease (STD) that is caused by human papillomavirus (HPV). Human papillomavirus is the name of a group of viruses that includes more than 100 different strains or types. More than 30 of these viruses are sexually transmitted, and they can infect the genital area of men and women including the skin of the penis, vulva (area outside the vagina), or anus, and the linings of the vagina, cervix, or rectum. Most people who become infected with HPV will not have any symptoms and will clear the infection on their own.

In June 2000, the National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the United States Agency for International Development (USAID), convened a workshop to evaluate the published evidence establishing the effectiveness of latex male condoms in preventing STDs, including HIV. A summary report from that workshop was completed in July 2001 (http://www.niaid.nih.gov/ dmid/stds/condomreport.pdf). This fact sheet is based on the NIH workshop report and additional studies that were not reviewed in that report or were published subsequent to the workshop (see link for additional references). Most epidemiologic studies comparing rates of STD transmission between condom users and non-users focus on penile-vaginal intercourse.

Not enough, according to Adam Glickman, owner of the Condomania stores in New York and Los Angeles. Glickman, who has sold condoms by the millions to individuals and organizations such as the Peace Corps and Planned Parenthood, says condoms should be viewed as ordinary, like toothpaste and toilet paper. "People have gotten past asking, 'Isn't brushing my teeth every morning a hassle?' Given the world we live in, wearing condoms is something you just have to do, like brushing your teeth. The stakes are too high."

An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

In testing, the gel, called tenofovir, was favorably self-applied and tolerable to non-HIV-infected women, a significant boost to HIV and AIDS prevention efforts focused on next-generation microbicides to reduce infection rates, the researchers said.

Newswise ? An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

In testing, the gel, called tenofovir, was favorably self-applied and tolerable to non-HIV-infected women, a significant boost to HIV and AIDS prevention efforts focused on next-generation microbicides to reduce infection rates, the researchers said.

The women study participants said if tenofovir gel is approved for the prevention of HIV infection, they would be willing to apply the gel to themselves daily or before sex, whichever is determined the best use.

?The gel is safe to use, and well tolerated by HIV-negative women. That?s a key message in our findings,? said Craig Hoesley, M.D., associate professor in the UAB Division of Infectious Diseases and author on the initial Phase II results. ?This sets the stage for larger studies to see if tenofovir can prevent HIV infection.?

The tenofovir Phase II trial results were presented Monday, Feb. 25 at an international microbicides meeting in New Delhi, India. The researchers are part of the U.S. National Institutes of Health-funded Microbicide Trials Network, an international team of researchers devoted to exploring and evaluating anti-HIV microbicides.

?Based on what we have learned we can proceed with greater confidence on a path that will answer whether tenofovir gel and other gels with HIV-specific compounds will be able to prevent sexual transmission of HIV in women when other approaches have failed to do so,? said Sharon L. Hillier, Ph.D., director of reproductive infectious disease research at the University of Pittsburgh School of Medicine and principal investigator on the Phase II study.

Researchers evaluated if tenofovir was safe to use every day for six months, or safe to use prior to each act of intercourse. They found both approaches equally safe. Women in the study were asked to use condoms in addition to the gel.

Researchers found no disruption of liver, blood or kidney function in each group of women using a different gel regimen, including those given a placebo gel that looked and felt identical to the tenofovir gel.

The study included 200 sexually active HIV-negative women enrolled at UAB, Bronx-Lebanon Hospital Center in New York and the National AIDS Research Institute in Pune, India. Participants were age 19 to 50, and 64 percent were married.

In addition to the safety findings, researchers found women in the study significantly willing to follow the gel-apply guidelines. Eighty percent of the women instructed to use the gel within two hours of having sex said they followed instructions, and 83 percent instructed to use the gel daily said they had done so in the week prior.

Hoesley said if the gel were approved to help prevent HIV infection, more than 90 percent of the study volunteers said they would seriously consider using it, regardless of the regimen, to protect their sexual health.

?We asked women ?How acceptable is this as a prevention option, is it too messy, is it a nuisance, and will you use it?? Our study showed they will use it and they?re not bothered by the gel,? Hoesley said.

The active ingredient in tenofovir gel is a class of anti-retroviral drugs called nucleotide reverse transcriptase inhibitors, which act against HIV by blocking the virus? ability to replicate and grow inside the body.

Tenofovir was developed by Gilead Sciences, Inc., of Foster City, Calif.

The Microbicide Trials Network was established in 2006 by the National Institute of Allergy and Infectious Diseases with co-funding from the National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the National Institutes of Health.

SOURCE: University of Alabama at Birmingham, NEWSWISE.COM

Keywords

Other Recent Articles

Stimulating Thymus Reactivates T-Cell Production » - It's possible to stimulate the thymus gland to produce new immune system T-cells in adults infected with HIV, U.S. researchers say.
HIV infection destroys T-cells, which leads to the collapse of the immune system and severe infection. The thymus gland produces T-cells early in life but gradually loses function and becomes mostly inactive in adulthood. That means it's difficult for HIV-infected adults to produce new T-cells to rebuild their depleted immune systems.

«HIV Stigmatization Still Widespread - Stereotypes and misinformation about HIV that are commonplace among the general public are also evident in a surprising number of clinical staff, a study from the University at Buffalo has found. Published in the journal AIDS Patient Care and STDs, Lance S. Rintamaki's study shows that more than 25 years after its discovery, HIV still has the power to generate a broad array of stigmatizing behavior. People infected with HIV have previously labeled dealing with stigma as the most significant social and psychological challenge of the HIV experience and Rintamaki's study shows little has changed.

» Discreet Plain Box Shipping For Your Privacy » We DO NOT Send Catalogs Or Mail » Established 1996